Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAMELEON: Trastuzumab Emtansine in HER2+ Solid Tumors
NCT02999672Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of trastuzumab emtansine in Urothelial Bladder Cancer (UBC), pancreatic cancer (PC), cholangiocarcinoma (CCA), sponsored by Roche. Started Dec 2016; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
Urothelial Bladder Cancer (UBC)pancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02999672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999672.